舒利迭在慢性阻塞性肺疾病稳定期的应用

目的 对比研究舒利迭（沙美特罗／丙酸氟替卡松）治疗慢性阻塞性肺疾病（COPD）的疗效。方法 对180例确诊为COPD的患者分成3组：分别吸入舒利迭（实验组）、施立稳（对照组1）、辅舒酮（对照组2），根据圣．乔治（St．George）呼吸疾病问卷（SGRQ）的方法对临床症状问卷调查及体征检查评分；测定肺功能指标FEVI、FEV1／FVC及FEV1占预计值的百分率（％），评价治疗前后肺功能的变化。结果临床症状积分及上述肺功能指标均获得了改善，与单独应用施立稳及辅舒酮组比较，舒利迭组治疗后临床症状积分及上述肺功能指标的改善更加显著（P〈0．01）。结论舒利迭是治疗COPD的有效的药物，其疗效明显优于应用其单一组。

Clinical application study of seretide in treatment of chronic obstructive pulmonary diseases

Objective To investigate the curative effect of seretide （ salmeterol/fluticasone propionate） in thetreatment of obstructive pulmonary diseases （COPD） by comparison. Methods 180 patients who sufferred from COPD were divided into 3 groups：experiment group （inhale seretide）, control group 1 （inhale salmeterol） and control group 2 （inhale fluticasone propionate）. According to the methods of standard grade of respiratory diseases questionnaire （SGRQ） introduced by St. George, the clinical symptom questionnaire and physical sign survey were graded. Subsequently, the percentage of pulmonary functional parameters including FEV1, FEVI or FVC and FEV1 in the anticipation value （%） were examined and then the pulmonary functional changes before and after therapy were evaluated. Results Clinical symptom integral and the above- mentioned pulmonary functional parameters in each group were improved, but the seretide group were improved more significantly than those in the single salmeterol and fluticasone propionate group. （P 〈 0. 01 ）. Conclusion Seretide is a effective medi- cine for COPD and its more significant curative effect than that of the single composition.